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Nonsteroidal anti-inflammatory drugs (NSAID) inhibit cyclooxygenase (COX) enzymes,
which exist in at least two isoforms, COX-1 and COX-2. Aspirin and older agents in this
class are nonselective inhibitors of both COX-1 and COX-2. Newer agents termed “coxibs”
are selective inhibitors of COX-2. Among the NSAID, only aspirin has been proven to
significantly reduce cardiovascular risk, primarily through inhibition of COX-1-mediated
platelet aggregation. It has been suggested that other nonselective agents, especially naproxen,
may provide some lesser degree of cardioprotection, but conclusive evidence is lacking.
Conversely, there are concerns that the COX-2 inhibitors may increase cardiovascular risk.
However, mechanisms for this potentially adverse cardiovascular effect are unknown, and it is
becoming increasingly clear that our understanding of the role of COX-2 in cardiovascular
function is incomplete. Some studies have demonstrated a potentially beneficial effect of
COX-2 on cardiovascular function that could be negated by COX-2 inhibition, while other
studies have reported improved endothelial function with COX-2 inhibitors. Additionally,
the impact of combined therapy with aspirin and other COX inhibitors is not yet clear. This
article will review the studies that have examined these issues. (J Am Coll Cardiol 2004;43:
519–25) © 2004 by the American College of Cardiology Foundationt
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lonsteroidal anti-inflammatory drugs (NSAID) are a het-
rogeneous class including aspirin and various other nonse-
ective and selective inhibitors of cyclooxygenase (COX).
spirin is the only NSAID used for prevention and treat-
ent of coronary heart disease (CHD). For primary pre-
ention, aspirin has been shown to reduce the risk of
ardiovascular events by 15% and myocardial infarction
MI) by 30% (1). The third U.S. Preventive Services Task
orce recommends low-dose aspirin for primary prevention
n patients at risk (2). Aspirin has also been shown to reduce
he risk of recurrent MI or other thrombotic vascular events
y approximately 25% (3). Practice guidelines from the
merican College of Cardiology and American Heart
ssociation recommend chronic low-dose aspirin for sec-
ndary cardiovascular prevention (4).
Many cardiovascular patients have comorbidities such as
usculoskeletal disorders that necessitate the use of other
SAID. These nonaspirin nonsteroidal anti-inflammatory
rugs (NANSAID) are among the most widely prescribed
rugs in the world, with an estimated 100 million prescrip-
ions in 1986 (5). Nonprescription use is also common. Use
f selective COX-2 inhibitors or “coxibs” has increased
ramatically since their introduction in 1999 (6). During
001, COX-2 inhibitors ranked sixth among the top 10
herapeutic classes prescribed in the U.S. with over $4.7
illion in annual sales (7).
From the *Department of Pharmacy Practice; and the †Division of Cardiovascular
iseases, University of Kansas Medical Center, Kansas City, Kansas. Bernard J.
ersh, MD, acted as the guest editor for this paper.
Manuscript received March 6, 2003; revised manuscript received June 3, 2003,lccepted September 10, 2003.With the widespread use of NANSAID, several impor-
ant clinical questions have emerged. First, studies have
eported an increased risk of cardiovascular events with
OX-2 inhibitors. Second, it has been suggested that some
onselective NANSAID, particularly naproxen, may have
ardioprotective effects. Finally, there has been debate over
he wisdom of combining aspirin with other NSAID. This
rticle will review the basis for these concerns and recent
rials addressing these issues.
HARMACOLOGY OF NSAID
he major mechanism of action for NSAID as shown in
igure 1 is inhibition of the COX enzymes that catalyze the
onversion of aracidonic acid to various eicosanoids including
hromboxane and various prostaglandins (5,8–10). Cyclooxy-
enase exists in at least two isoforms designated as COX-1 and
OX-2 (9–11). The two isoforms are encoded by different
enes and have unique patterns of expression. The COX-1
sozyme is essential for the maintenance of normal physiologic
tates in many tissues including the kidney, gastrointestinal
ract, and platelets. For example, COX-1 activation in the
astric mucosa leads to prostacyclin production, which is
ytoprotective (12). The COX-2 isozyme is induced by various
nflammatory stimuli including cytokines, endotoxins, and
rowth factors. The COX enzymes play an important role in
ardiovascular homeostasis. Thromboxane A2, which is pri-
arily synthesized in platelets through COX-1 activity, causes
latelet aggregation, vasoconstriction, and smooth muscle pro-
iferation. Conversely, prostacyclin (PG I2) synthesis, which is
argely mediated by COX-2 activity in macrovascular endothe-
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Cardiac Effects of NSAID February 18, 2004:519–25ial cells, counteracts these effects resulting in inhibition of
latelet aggregation, vasodilation, and antiproliferative effects
10).
Nonsteroidal anti-inflammatory drugs vary in their rela-
ive inhibitory effects on COX-1 and COX-2 (10,11).
spirin is approximately 166 times more potent an inhibitor
f COX-1 as compared with COX-2 (13). Aspirin irrevers-
bly acetylates and inhibits the COX-1 isozyme resulting in
omplete platelet inhibition for the life of the platelet (8).
ther nonselective NANSAID (e.g., naproxen, ibuprofen)
ause varying degrees of COX-1 and COX-2 inhibition and
roduce reversible platelet inhibition (8,10). Studies in vivo
ave shown that 95% suppression of platelet COX-1 activ-
ty is needed to inhibit thromboxane A2-dependent platelet
ggregation (14). While this degree of inhibition is obtained
ith low-dose aspirin, other nonselective NANSAID pro-
uce variable COX inhibition ranging from 50% to 95% in
reversible time-dependent fashion (15). This inhibitory
attern may be insufficient to provide cardioprotection
hroughout the dosing interval and may explain the greater
ardiovascular protection provided by aspirin.
In an attempt to overcome the gastrointestinal toxicity
nd hemorrhagic risk associated with nonselective NSAID,
he selective COX-2 inhibitors were developed for the
Abbreviations and Acronyms
CHD  coronary heart disease
CLASS  Celecoxib Long-term Arthritis Safety
study
COX  cyclooxygenase
MI  myocardial infarction
NANSAID  nonaspirin nonsteroidal anti-inflammatory
drugs
NSAID  nonsteroidal anti-inflammatory drugs
VIGOR  Vioxx Gastrointestinal Outcomes Research
study
igure 1. Action of nonsteroidal anti-inflammatory drugs (NSAID).
rachidonic acid, liberated from membrane phospholipids in response to
ultiple stimuli, is converted to prostaglandin H2 by cytosolic prostaglan-
in G/H synthases (cyclooxygenase [COX]-1 and -2). Prostaglandin H2 is
onverted by tissue-specific isomerases to multiple prostanoids. Aspirin and
ther nonselective nonaspirin nonsteroidal anti-inflammatory drugs
NANSAID) inhibit both COX-1 and -2, whereas coxibs selectivelycnhibit COX-2.reatment of inflammation and pain (16). This class includes
ofecoxib and celecoxib, which are widely used in the U.S.;
toricoxib, which was recently introduced in the United
ingdom; and agents under development, such as lumira-
oxib and meloxicam. Because platelets primarily express
he COX-1 isozyme, these drugs would not be expected to
ossess antithrombotic properties. However, even among
hese agents, the relative selectivity toward COX-2 varies.
or example, both rofecoxib and etoricoxib have greater
OX-2 selectivity than celecoxib. In addition, the role of
OX-2 in cardiovascular function remains unclear. Re-
ently, concerns have been raised that some COX-2 inhib-
tors may actually promote thrombosis.
ELECTIVE COX-2 INHIBITORS AND
ARDIOVASCULAR OUTCOMES
tudies have suggested a possible link between COX-2
nhibitors and increased cardiovascular risk (Table 1). To
ate, no completed prospective trials have specifically ad-
ressed this issue. However, clinical trials of COX-2 inhib-
tors designed to examine gastrointestinal outcomes have
eported cardiovascular events. Unfortunately, the findings
rom these clinical trials, which used different COX-2
nhibitors, have been inconsistent.
Concerns of potentially adverse cardiovascular effects
nitially resulted from clinical studies involving rofecoxib.
he Vioxx Gastrointestinal Outcomes Research study
VIGOR) (17) compared rofecoxib 50 mg daily to naproxen
00 mg twice daily in 8,076 rheumatoid arthritis patients.
atients with recent cardiovascular events or those taking
spirin were excluded. The primary end point was upper
astrointestinal events. Unexpectedly, the study found a
igher incidence of MI with rofecoxib compared with
aproxen (0.4% vs. 0.1%; 95% confidence interval, 0.1% to
.6%). Investigators were uncertain whether the increased
I risk was due to a detrimental effect of rofecoxib or the
rohibition of aspirin use. Further analysis showed that the
% of patients who qualified as aspirin candidates for
econdary cardiovascular prevention accounted for 38% of
he MIs. Among patients without indications for aspirin
rophylaxis, MI rates were not significantly different be-
ween rofecoxib and naproxen. These findings led investi-
ators to suggest the observed differences could be due to a
rotective naproxen effect. Gastrointestinal bleeding, a po-
ential indicator of antithrombotic effects, was significantly
ower with rofecoxib as compared with naproxen (relative
isk, 0.4; 95% confidence interval, 0.3 to 0.6).
In contrast with VIGOR, the Celecoxib Long-term
rthritis Safety study (CLASS) found no increased risk of
I (18). This trial included 8,059 patients with osteoar-
hritis or rheumatoid arthritis. The primary end point was
pper gastrointestinal toxicity. Patients were treated with
elecoxib 400 mg twice daily or another nonselective COX
i
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February 18, 2004:519–25 Cardiac Effects of NSAIDnhibitor (ibuprofen 800 mg three times daily or diclofenac
5 mg twice daily). The trial was not placebo-controlled,
nd naproxen was not evaluated. Aspirin in daily doses up to
25 mg for cardioprotection was permitted and used by
pproximately 20% of patients in both the celecoxib and
ANSAID groups. The two treatment groups showed no
tatistically significant difference in MI rates or total car-
iovascular events, although numerically there were more
Is in the celecoxib group. Although no differences in
ardiovascular outcomes relative to aspirin use were appar-
nt, the trial was not designed to examine differences
etween aspirin users and nonusers. Total bleeding rates
ere higher with NANSAID compared with celecoxib
6.0% vs. 3.1%, respectively). The impact of combined
spirin-NSAID use on bleeding could not be determined
ue to the low rate of aspirin use.
It should be noted that the two comparator agents in
LASS, diclofenac and ibuprofen, have relatively weak anti-
latelet effects (6). Effects of combined therapy with aspirin
nd various NANSAID on serum thromboxane B2 concen-
able 1. Summary of Selected NSAID Studies Evaluating CV R
Study Population n Histor
Clinical Studies
IGOR (17) RA 8,076 4% know
Excluded
with rec
events
LASS (18) OA/RA 8,059 Not exclu
atsumoto et al. (20) RA 816 Excluded
Pooled Analyses of CO
eicin et al. (21) OA 5,435 12% know
onstam et al. (22) Mixed 28,000 Not exclu
Observational Stud
amdani et al. (24) Mixed 66,964 Not exclu
Observational Studies of N
olomon et al. (25) Mixed 4,425 cases Excluded
17,700 controls
atson et al. (26) RA 809 cases Excluded
2,285 controls
ahme et al. (27) Mixed 4,163 cases Not exclu
recent
14,160 controls
ay et al. (28) Mixed 181,441 cases Not exclu
181,441 controls
Undisclosed nonprescription aspirin (ASA) use cannot be ruled out.
CHD coronary heart disease; COX cyclooxygenase; CV cardiovascular; GI
rugs; NANSAID  nonaspirin nonsteroidal anti-inflammatory drugs; OA  osteorations, an indicator of platelet COX-1 enzyme activity and elatelet aggregation, have been studied in healthy volunteers
8). Concomitant administration of ibuprofen, but not diclofe-
ac or rofecoxib, antagonized the platelet-inhibiting effects of
spirin. This finding is furthered supported by a recent epide-
iological study of 7,107 patients with cardiovascular disease
19). Concomitant ibuprofen therapy blunted aspirin’s cardio-
rotective effect resulting in a twofold increased risk of death
nd a 75% increased risk of cardiovascular disease. These
ndings raise concerns about concomitant aspirin-ibuprofen
se and suggest differences in the modulation of aspirin’s
ardioprotection by various NANSAID.
Cardiovascular outcomes have also been reported from a
linical trial of etoricoxib, a highly selective COX-2 inhibitor
20). This 12-week efficacy trial included 816 patients with
heumatoid arthritis. Patients received etoricoxib 90 mg daily,
aproxen 500 mg twice daily, or placebo. Patients with known
ardiovascular disease were excluded. However, patients were
llowed to take aspirin up to 100 mg daily. There were two
onfirmed adjudicated cardiovascular events in the trial, both in
atients taking etoricoxib. One clinically significant bleeding
HD ASA Allowed* Cardiovascular Outcomes
X 2 Inhibitors
D
nts
V
No Increased MI rate with rofecoxib vs.
naproxen CV death rates similar
Yes 325 mg Similar CV event rates for celecoxib
and NANSAID
Yes 100 mg 2 CV events with etoricoxib vs. 0
events with naproxen
nhibitor Clinical Trials
D No Similar CV event rates with rofecoxib,
NANSAID, and placebo
Variable among
trials
Increased CV events with rofecoxib vs.
naproxen but not other NANSAID
COX 2 Inhibitors
Yes Similar CV event rates for celecoxib,
rofecoxib, naproxen, other
NANSAID vs. controls
en and Other NANSAID
No Decreased MI rate with naproxen but
not other NANSAID vs. nonusers
No Decreased CV events with naproxen
nless Yes Decreased MI rate with naproxen vs.
other NANSAID
Yes Decreased MI rate with naproxen vs.
ibuprofen
Similar MI rate for naproxen vs.
nonusers
trointestinal; MI myocardial infarction NSAID nonsteriodal anti-inflammatory
is; RA  rheumatoid arthritis.isk
y of C
of CO
n CH
patie
ent C
ded
X 2 I
n CH
ded
ies of
ded
aprox
ded u
event
ded
 gas
arthritvent was reported in a naproxen patient.
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Cardiac Effects of NSAID February 18, 2004:519–25In response to these conflicting results, several secondary
nalyses have been performed to examine cardiovascular risk.
ukherjee et al. (6) performed additional analyses on data
rom VIGOR and CLASS (6). The annualized MI rates for
oth trials were compared with those of 23,407 placebo
atients not taking aspirin from a meta-analysis (1) of four
ublished primary prevention trials. As compared with the
nnualized MI rate of 0.52% for the placebo patients, the
nnualized MI rates were increased with both rofecoxib
0.74%, p  0.04) and celecoxib (0.80%, p  0.02).
Another study examined the risk of thrombotic cardiovas-
ular events among patients receiving rofecoxib, and nonselec-
ive NANSAID (ibuprofen, diclofenac, or nabumetone) or
lacebo. Safety was assessed using a database of 5,435 partic-
pants in eight rofecoxib osteoarthritis clinical trials (21). After
median treatment duration of 3.5 months, no differences in
ardiovascular risk were found between rofecoxib, comparator
onselective NSAID, and placebo.
A pooled data analysis was conducted from 23 rofe-
oxib clinical trials involving over 28,000 patients and
4,000 patient-years of risk (22). Indications for rofe-
oxib included rheumatoid arthritis, osteoarthritis, back
ain, and Alzheimer’s prevention. The primary outcome
as a combined vascular end point similar to that used in
he Antiplatelet Trialists Collaboration (3) including
ardiovascular hemorrhagic and unknown deaths, nonfa-
al MI, and nonfatal strokes. In this pooled analysis (22),
o excess thrombotic events were found when rofecoxib
as compared with placebo or a nonselective NANSAID
ther than naproxen (diclofenac, ibuprofen, nabum-
tone). However, the risk of thrombotic events was
igher with rofecoxib compared with naproxen alone
relative risk, 1.69; 95% confidence interval, 1.07 to
.69). The study investigators attributed the difference to
protective effect of naproxen, noting that near-complete
latelet inhibition can be achieved throughout the dosing
nterval with naproxen doses of 500 mg twice daily.
White et al. (23) further analyzed the CLASS data to
ssess cardiovascular risk for celecoxib and other NAN-
AID. The analyses included 3,987 persons randomized to
elecoxib and 3,981 persons randomized to a comparator.
ates for serious cardiovascular events defined as MI,
troke, cardiovascular death, and peripheral events were
imilar for celecoxib and the comparators ibuprofen or
iclofenac for all patients and an aspirin subgroup. No
ignificant differences were found for combined event rates
r individual event rates including MI.
A large Canadian retrospective cohort study (24) examined
he risk of MI with various NSAID. The study included
5,271 celecoxib patients, 12,156 rofecoxib patients, 5,669
aproxen patients, 33,868 NANSAID patients, and 100,000
andomly selected control patients. In contrast with other
tudies, no increased risk of MI was found with either COX-2
nhibitor. Additionally, no decreased risk of MI was observed
ith naproxen or other NANSAID. (ONSELECTIVE NANSAID AND CARDIOVASCULAR
UTCOMES
bservational case-control studies have suggested a possible
ardioprotective effect with naproxen (Table 1) (25–28). A
etrospective study using a New Jersey Medicare and Med-
caid patient database compared NANSAID use among
,425 patients hospitalized for MI and 17,700 controls (25).
verall, NANSAID users had the same MI risk as nonus-
rs. However, naproxen use was associated with a significant
eduction in MI risk (odds ratio, 0.84; 95% confidence
nterval, 0.72 to 0.98; p  0.03).
A retrospective study from the United Kingdom exam-
ned the risk of acute thromboembolic cardiovascular events
MI, sudden death, and stroke) in rheumatoid arthritis
atients receiving naproxen (26). A total of 809 cases were
atched with up to four control patients each. Compared
ith patients with no documented naproxen use during the
ear before a thrombotic event, naproxen within the previ-
us 30 days significantly reduced the risk of an event (odds
atio, 0.61; 95% confidence interval, 0.39 to 0.94). Con-
ersely, no protective effect was seen with other NANSAID
ombined or with ibuprofen or diclofenac alone.
A retrospective Canadian study compared naproxen to
ther NANSAID for secondary MI prophylaxis in patients
65 years of age hospitalized for MI (27). The study
ncluded 4,163 cases and 14,160 controls matched for age,
ender, and date of index event. Naproxen therapy reduced
he risk of MI as compared with other NANSAID (odds
atio, 0.79; 95% confidence interval, 0.63 to 0.99).
A prospective study using Tennessee Medicaid patients
xamined a cohort of 181,441 new NANSAID users who were
ge- and gender-matched to an equal number of nonuser
ontrols (28). The study included patients 50 to 84 years of age
ith 532,634 person-years of follow-up. The primary end
oint was hospitalization for MI or death from CHD. Overall,
he study found similar risks for MI among current naproxen
sers compared with nonusers. However, when directly com-
ared with ibuprofen users, the risk of MI was lower with
aproxen (odds ratio, 0.83; 95% confidence interval, 0.69 to
.98). It was not clear if this difference was due to a protective
aproxen effect or a detrimental effect of ibuprofen.
One additional observational study has examined whether
ANSAID use after MI was associated with a protective
ffect similar to that of aspirin (29). Data were analyzed
rom 48,584 Medicare patients in the Cooperative Cardio-
ascular Project hospitalized for MI with no known contra-
ndications to NSAID. At discharge, 1.5% of patients were
rescribed NANSAID, 74.5% were prescribed aspirin, 4.3%
eceived prescriptions for both drugs, and 19.6% received
either drug and served as controls. The primary outcome
as mortality within one year of hospital discharge. Com-
ared with controls, the hazard ratios were 0.77 (95%
onfidence interval, 0.65 to 0.90) for NANSAID, 0.81
95% confidence interval, 0.77 to 0.86) for aspirin, and 0.78
95% confidence interval, 0.69 to 0.88) for combined
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February 18, 2004:519–25 Cardiac Effects of NSAIDherapy. Overall, the cardioprotective effects of NANSAID
nd aspirin were similar with no additional benefit associ-
ted with combined therapy. Interestingly, naproxen ac-
ounted for only 13% of the NANSAID prescriptions.
ifferences between the various NANSAID were not eval-
ated, and the COX-2 inhibitors were not available. This is
he first study reporting similar survival benefits after MI for
ANSAID and aspirin. However, due to the retrospective
esign, these findings should be interpreted with caution.
OLE OF COX-2 IN CARDIOVASCULAR FUNCTION
t has been suggested that COX-2 inhibitors may increase
ardiovascular risk by promoting thrombosis. This hypoth-
sis is not without merit because these agents lack antiplate-
et effects (due to minimal COX-1 inhibition) and decrease
rostacyclin (PGI2) production, which has vasodilating,
ntiaggregatory, and antiproliferative properties (17,30).
hus, it has been suggested that the increased cardiovascu-
ar risk may result from unopposed thromboxane A2 actions.
n addition, various experimental models have suggested a
ardioprotective role for the COX-2 isozyme that might be
locked by COX-2 inhibitors. Cyclooxygenase-2 is ex-
ressed at low levels by endothelial cells under static
onditions but induced under conditions of laminar shear
tress (31). These findings suggest that decreased prostacy-
lin secondary to COX-2 deficiency may increase the risk of
ocal atherogenesis at sites of vascular bifurcation. It has also
een shown in conscious rabbits that COX-2 mediates
ardioprotective effects during the late phase of ischemic
reconditioning (32). However, administration of COX-2
nhibitors to the rabbits 24 h after ischemic preconditioning
liminates the cardioprotective effect of late ischemic pre-
onditioning against myocardial stunning and MI. These
nd subsequent studies have demonstrated that upregulation
f COX-2 plays a key role in cardioprotection, which may
e mediated through PGE2 and PGI2 (32,33). Other
tudies using a canine coronary thrombosis model found
hat the administration of a COX-2 inhibitor abolishes the
ncreased time to arterial occlusion produced by aspirin (34).
tudies in a rat model demonstrated that the chemotherapy
rug doxorubicin induces COX-2 activity in neonatal myo-
ytes, which, in turn, limits the drug-induced cardiotoxicity.
owever, administration of COX-2 inhibitors attenuated
his cardioprotective effect (35). In addition, a recent study
n mice suggests that COX-2 inhibitors may increase vascular
esponse to injury as well as thromboxane A2 synthesis and
latelet activation (36). The study used genetically engineered
ice that either overexpress or lacked receptors for thrombox-
ne A2 and/or prostacyclin. In mice lacking the prostacyclin
eceptor, mechanical injury to carotid vessels led to obstruction.
n this scenario, which mimics selective COX-2 inhibition,
hromboxane A2 was overproduced by both platelets and the
njured vessel wall. In contrast, the obstructive response was
uted in mice who lacked either the thromboxane A2 receptor
r both receptors.IMITATIONS OF THE CURRENT EVIDENCE
vidence for increased cardiovascular risk with COX-2
nhibitors is inconclusive. None of the randomized trials
ere powered to examine cardiovascular outcomes, thus
ntroducing the possibility of bias. Baseline cardiovascular
isk varied significantly among the studies. The VIGOR
tudy was conducted in patients with rheumatoid arthritis, a
isease associated with significant cardiovascular risks (37).
onversely, CLASS included primarily patients with osteo-
rthritis, which is not associated with increased cardiovas-
ular risk. The secondary analyses of the VIGOR and
LASS data by Mukherjee et al. (6) have also raised
ethodological concerns (38) regarding the validity of
omparing crude MI rates from high-risk rheumatoid ar-
hritis patients to a placebo group constructed from low-risk
atients in primary prevention trials. The analyses of 23
ofecoxib clinical trials with a mixed patient population
ncluding rheumatoid arthritis, osteoarthritis, Alzheimer’s
isease, and back pain failed to show an increased throm-
otic risk (22). Additionally, the analyses of 5,435 partici-
ants in the rofecoxib osteoarthritis development program
ound no difference in cardiovascular events between rofe-
oxib, comparator nonselective NSAID, and placebo (21).
herefore, while it is possible that COX-2 inhibitors
ncrease cardiovascular risk, the data are inconsistent, and it
s likely that baseline patient risk plays a significant role.
Furthermore, it is not yet clear whether there are differ-
nces between COX-2 inhibitors because studies of cele-
oxib have not reported increased cardiovascular events (18).
s previously noted, the COX-2 selectivity of celecoxib is
ess than that of rofecoxib. At daily doses of 400 mg twice
aily (similar to CLASS doses), celecoxib has been shown
o produce some COX-1 inhibition and a degree of selec-
ivity similar to the nonselective agent diclofenac (39).
dditional studies are needed to examine the impact of
OX selectivity.
The hypothesis that a cardioprotective effect of naproxen
ay explain the VIGOR findings is plausible but inconclu-
ive. Naproxen has been shown to be a stronger inhibitor of
OX-1 than either ibuprofen or diclofenac (40). Inhibition
f thromboxane by 95% and platelet aggregation by 88% has
een shown with naproxen during a typical dosing interval.
n addition, diclofenac causes 94% inhibition of COX-2
ompared with 71% with naproxen (40). To date, no
rospective clinical trials have evaluated naproxen for car-
ioprotection. Interpretations from observational studies are
ubject to the many limitations inherent to this design
ncluding the inability to prove causation. Although the data
uggest that naproxen may be advantageous over other
onselective NANSAID, the degree of cardioprotection is
ot of the magnitude of aspirin (41). Finally, because
OX-2 inhibitors were not included in the naproxen
tudies, the findings do not provide a definitive explanation
or the increased cardiovascular risk in the rofecoxib studies.Additionally, the cardiovascular impact of combined
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Cardiac Effects of NSAID February 18, 2004:519–25herapy with aspirin remains unclear. None of the studies
ere adequately powered to specifically address this ques-
ion, and nonprescription or unreported use of aspirin could
ot be controlled. Recently, improved endothelial function
as reported with celecoxib in CHD patients previously
tabilized on aspirin and statins (42). In crossover fashion,
4 males received celecoxib 200 mg twice daily or placebo
or two weeks. As measured by flow-mediated brachial
rtery vasodilation, celecoxib significantly improved
ndothelium-dependent vasodilation compared with placebo.
dditionally, both C-reactive protein and oxidized low-density
ipoprotein were significantly lower with celecoxib. This is the
rst study suggesting that a COX-2 inhibitor might improve
ndothelium function and reduce low-grade inflammation and
xidative stress in patients with severe CHD. Additionally, a
ecent pilot study found that addition of the COX-2 inhibitor
eloxicam to low-dose aspirin and heparin improved clinical
utcomes after non-ST-segment elevation acute coronary syn-
romes (43). These small studies suggest that combined aspirin
nd COX-2 inhibition could have beneficial cardiovascular
ffects.
Additional prospective trials are needed to assess the cardio-
ascular risks of NSAID. The upcoming gastrointestinal safety
rial for lumiracoxib will evaluate cardiovascular events as a
econdary end point and include patients taking low-dose
spirin for cardioprotection. Ibuprofen and naproxen will serve
s comparators in this 12-month trial, which should address
any of the ongoing concerns. However, because all of the
ssues that have been raised cannot be examined in clinical trials
or various practical and ethical reasons, there is also a need for
ong-term postmarketing studies and well-designed epidemi-
logical studies. In particular, further study is needed to
xamine the impact of combined therapy with aspirin and
ther NSAID on bleeding.
ONCLUSIONS
ecent study findings have demonstrated that our present
nderstanding of the impact of COX inhibition on cardio-
ascular risk is incomplete. Studies are needed to determine
he comparative cardiovascular effects of various COX-2
nhibitors and the impact of baseline risk. Cardioprotective
ffects of naproxen and other nonselective NANSAID
hould also be studied further but, in the absence of
efinitive data, these agents should not replace aspirin.
inally, the cardiovascular impact of various combinations
f aspirin and other COX inhibitors requires further study.
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